article · Haemophilia

Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors

Amy L. Dunn
Giancarlo Castaman
Cédric Hermans
Michael Recht
Yesim Dargaud
Magdalena Lewandowska
Víctor Jiménez‐Yuste
Vanessa Salinas
Shannon L. Meeks
Manuel Carção
Yasmina L. Abajas
Thomas A. Wilkinson
Tammuella Chrisentery‐Singleton
Ian S. Mitchell
Adam Giermasz
Wolfgang Miesbach
Johnny Mahlangu
Daniel Bonzo
Guy Young

20241 citationOpen accessUniversity of the Witwatersrand

Abstract

Subjects with haemophilia with inhibitors who used eptacog beta to treat mild/moderate BEs experienced a low incidence of rebleeding. Rebleeds that did occur were effectively controlled with eptacog beta (median, one dose) without the need for hospitalization.

Research topics

Hemophilia Treatment and Research
Hemostasis and retained surgical items
Platelet Disorders and Treatments

Sustainable Development Goals

Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1111/hae.15109

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.